XRAY Director Acquires 2,638 Phantom Stock Shares, May 07, 2026

Insider trading activity reveals what company leaders truly believe about their business. When executives and directors acquire shares, it sends a powerful signal to the market. Today we examine a significant insider transaction at XRAY (DENTSPLY SIRONA Inc.), where a director acquired phantom stock units through the company’s deferred compensation plan. This insider trading move occurred on December 31, 2025, and was filed with the SEC on January 2, 2026. Understanding these insider transactions helps investors gauge management confidence in the company’s future direction.

Director Acquires Phantom Stock Through Deferred Compensation Plan

Jonathan Jay Mazelsky, a director at DENTSPLY SIRONA, acquired 2,638 phantom stock units on December 31, 2025. This transaction represents an award under the company’s Directors’ Deferred Compensation (DDC) plan. Phantom stock is a form of equity compensation that tracks the value of actual company shares without granting voting rights. The SEC filing shows Mazelsky now holds 14,382 phantom stock units total. This acquisition demonstrates the company’s commitment to retaining board leadership through equity-based incentives.

What Is Phantom Stock?

Phantom stock is a compensation tool that mimics real stock ownership without actual share issuance. Directors receive units that increase in value alongside the company’s stock price. When the director leaves the board or retires, the company pays cash equal to the phantom stock’s value. This approach aligns director interests with shareholder returns while maintaining flexibility in capital structure. DENTSPLY SIRONA uses this method to attract and retain experienced board members.

Award vs. Purchase: Understanding the Transaction Type

This transaction is classified as an “A-Award,” meaning Mazelsky received the phantom stock as compensation rather than purchasing it with personal funds. Awards typically occur annually or upon board appointment. The December 31 date suggests this was a year-end compensation grant. Unlike open market purchases, awards don’t indicate personal conviction about stock price direction. However, they do show the company values Mazelsky’s continued board service and strategic guidance.

Insider Trading Signal: What This Acquisition Means

Director acquisitions through compensation plans carry different weight than open market purchases. When insiders buy shares with their own money, it signals strong confidence. Awards, however, are routine compensation events. Still, the fact that Mazelsky accepted and retained phantom stock units suggests he believes in DENTSPLY SIRONA’s long-term value. The company’s market cap of $2.23 billion reflects its position as a major player in dental equipment and technology.

Board Confidence and Retention

Director compensation awards serve a dual purpose: rewarding service and retaining talent. By granting phantom stock, DENTSPLY SIRONA ensures board members remain invested in company performance. Mazelsky’s growing phantom stock position (now 14,382 units) shows he has accumulated significant equity exposure over time. This accumulation pattern suggests long-term commitment to the company’s strategic direction and governance.

Market Context for XRAY

DENTSPLY SIRONA operates in the dental equipment and technology sector, a stable industry with consistent demand. The company serves dentists, orthodontists, and dental labs worldwide. Insider activity at this level provides insight into management’s confidence in market conditions and company strategy. Meyka AI rates XRAY a grade of B, reflecting solid fundamentals and sector performance relative to the S&P 500.

SEC Filing Details and Compliance

The insider transaction was reported on Form 4, the standard SEC document for officer and director trades. DENTSPLY SIRONA filed the disclosure on January 2, 2026, within the required two-business-day window. The filing identifies Mazelsky as a director and classifies the security as Phantom Stock (Directors’ Deferred Compensation) DDC. No price per share was listed because phantom stock awards don’t involve cash transactions at grant time.

Form 4 Filing Requirements

Form 4 filings must disclose all insider transactions within two business days of execution. Directors, officers, and major shareholders must report acquisitions and dispositions. The form includes transaction date, number of shares, security type, and beneficial ownership after the transaction. DENTSPLY SIRONA’s filing met all SEC requirements and provides transparency to investors monitoring insider activity.

Beneficial Ownership After Transaction

After acquiring 2,638 phantom stock units, Mazelsky’s total beneficial ownership reached 14,382 units. This represents his accumulated equity stake through the deferred compensation plan. The growing position indicates Mazelsky has participated in multiple annual awards or grants. Tracking beneficial ownership helps investors understand how deeply insiders are invested in company success.

What Investors Should Know About This Insider Activity

This single insider transaction provides limited predictive power for stock price movement. One director’s compensation award doesn’t constitute a major buying signal. However, it does confirm that DENTSPLY SIRONA’s leadership values board continuity and long-term planning. Investors should monitor whether additional insiders make open market purchases, which would signal stronger conviction. The absence of director sales is also noteworthy, suggesting no major concerns about company prospects.

Monitoring Insider Activity Trends

Investors benefit from tracking insider transactions over time rather than reacting to individual events. Patterns matter more than isolated trades. If multiple directors or executives begin selling shares, that warrants attention. Conversely, sustained acquisitions across the leadership team indicate confidence. DENTSPLY SIRONA’s insider activity should be reviewed quarterly to identify meaningful trends in management sentiment.

Using Insider Data for Investment Decisions

Insider transactions are one data point among many. They should be combined with financial analysis, industry trends, and valuation metrics. Phantom stock awards are routine compensation, not necessarily bullish signals. However, they do confirm that insiders believe the company will remain viable and valuable. Investors should use this information alongside earnings reports, analyst ratings, and market conditions when making decisions.

Final Thoughts

Jonathan Jay Mazelsky’s acquisition of 2,638 phantom stock units through DENTSPLY SIRONA’s deferred compensation plan represents routine director compensation rather than a major insider buying signal. The transaction, executed on December 31, 2025, and filed on January 2, 2026, brings his total phantom stock holdings to 14,382 units. While this award doesn’t indicate personal conviction about stock price direction, it does confirm board leadership’s commitment to the company’s long-term success. Investors should view this transaction as part of normal compensation practices while continuing to monitor broader insider activity patterns for meaningful signals about management confidence in…

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.